Week in Review: Boehringer Ingelheim Corporation to Build Biopharma CMO in Shanghai  
6/10/2013 9:16:34 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

June 8, 2013 -- Boehringer Ingelheim will build a cGMP CMO facility in Shanghai’s Zhangjiang Hi-Tech Park in cooperation with Zhangjiang Biotech and Pharmaceutical Base Development Co. and funded with an $81 million joint investment; the China Securities Regulatory Commission terminated the IPO applications of fifteen China life science companies; Janssen Pharma and the National Taiwan University Hospital will co-develop new drugs for hepatitis B; Genor Biopharma of Shanghai has agreed with BioCND, a Korean biosimilar CRO, to co-develop biosimilars of Humira and Herceptin; China’s Center for Disease Control and Prevention will team up with The Center for Infection and Immunity (CII) of Columbia University to form a Pathogen Discovery lab, housed in China’s CDCP; AngioLight, a cardiovascular medical device company located in Massachusetts, completed a successful initial animal study of its AngioLight™ System at Fu Wai Hospital in Beijing; and more than 750 forward-thinking industry executives converged upon Beijing last week for the ChinaBio® Partnering Forum, China’s premier life science partnering event. More details....

Help employers find you! Check out all the jobs and post your resume.